Antibody-drug conjugates have become one of the most actively validated areas in oncology. By combining the targeting precision of antibodies with the cytotoxic potency of chemotherapy payloads, ADCs have attracted billions in pharma M&A and partnership activity over the past several years, and the pipeline continues to grow.
The company's focus is on multi-payload ADCs: a next-generation approach that enables multiple distinct drugs to be attached to a single antibody. Early data show strong efficacy alongside an encouraging safety profile against some of the most difficult targets in oncology.
LongeVC first backed CatenaBio as part of our Fund I portfolio, and we are proud to announce that we have now followed on in their Series A. The team, led by Marco Lobba, Ph.D., brings together deep scientific and industry expertise, and we look forward to continuing the journey with them as they advance this platform.
Learn more about CatenaBio here.
The company's focus is on multi-payload ADCs: a next-generation approach that enables multiple distinct drugs to be attached to a single antibody. Early data show strong efficacy alongside an encouraging safety profile against some of the most difficult targets in oncology.
LongeVC first backed CatenaBio as part of our Fund I portfolio, and we are proud to announce that we have now followed on in their Series A. The team, led by Marco Lobba, Ph.D., brings together deep scientific and industry expertise, and we look forward to continuing the journey with them as they advance this platform.
Learn more about CatenaBio here.